Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

1.42
0.0000
Post-market: 1.40-0.0183-1.29%17:15 EST
Volume:2.34M
Turnover:3.32M
Market Cap:319.12M
PE:-1.45
High:1.46
Open:1.43
Low:1.38
Close:1.42
52wk High:3.78
52wk Low:0.8621
Shares:224.73M
Float Shares:168.00M
Volume Ratio:1.01
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9781
EPS(LYR):-1.3222
ROE:-54.43%
ROA:-27.34%
PB:1.01
PE(LYR):-1.07

Loading ...

BRIEF-Allogene Therapeutics Q3 EPS USD -0.19

Reuters
·
Nov 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 06

Allogene Therapeutics Unveils Pivotal Phase 2 ALPHA3 Trial of Cema-cel in Large B-Cell Lymphoma

Reuters
·
Nov 03

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 30

Allogene Therapeutics CFO Geoffrey M. Parker Reports Sale of Common Shares

Reuters
·
Oct 24

Allogene Therapeutics Faces Potential Risk as Cellectis Hit with Patent Infringement Lawsuit Over TALEN Gene-Editing Technology

Reuters
·
Oct 14

J.P. Morgan Sticks to Its Sell Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
Oct 10

U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity

Reuters
·
Oct 10

Allogene Therapeutics Inc : JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
Oct 10

Allogene Therapeutics Initiates Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma

Reuters
·
Aug 14

Allogene Therapeutics Reports Quarterly Financial Results; Key Milestones Achieved in Clinical Trials

Reuters
·
Aug 14

BRIEF-Allogene Therapeutics Q2 EPS USD -0.23

Reuters
·
Aug 14

Allogene Therapeutics Q2 Net Income USD -50.943 Million

THOMSON REUTERS
·
Aug 14

Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC

GlobeNewswire
·
Aug 08

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

THOMSON REUTERS
·
Aug 06

JPMorgan Downgrades Allogene Therapeutics to Neutral From Overweight

MT Newswires Live
·
Aug 04

U.S. RESEARCH ROUNDUP-Carvana, Federated Hermes, Ralph Lauren

Reuters
·
Aug 04

Allogene Therapeutics Inc : JP Morgan Cuts to Neutral From Overweight

THOMSON REUTERS
·
Aug 04

Allogene Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview

Reuters
·
Aug 02

BRIEF-Allogene Therapeutics Selects Standard FC Regimen For Alpha3 Study - SEC Filing

Reuters
·
Aug 01